BRIEF-Aprea Reports Promising Early Data for WEE1 Inhibitor in HPV+ HNSCC with MD Anderson

Reuters
25 Jun
BRIEF-Aprea Reports Promising Early Data for WEE1 Inhibitor in HPV+ HNSCC with MD Anderson

June 25 (Reuters) - Aprea Therapeutics Inc APRE.O:

  • APREA REPORTS ANTI-PROLIFERATIVE RESULTS AND PROMISING EARLY-STAGE CLINICAL DATA FOR NEXT-GENERATION WEE1 INHIBITOR, APR-1051, IN HPV+ HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IN COLLABORATION WITH MD ANDERSON CANCER CENTER

  • APREA THERAPEUTICS INC - PHASE 1 UPDATE SHOWS EARLY DISEASE CONTROL IN HPV+ PATIENT

Source text: ID:nGNXbt7Z3h

Further company coverage: APRE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10